Sihuan Pharmaceutical Announces Major Milestone: Approval for Xuanzhu Biopharm H Share Full Circulation

Key Highlights of the Announcement

• Stock Exchange Approval: On 16 April 2026, the Stock Exchange of Hong Kong Limited granted approval to Xuanzhu Biopharmaceutical Co., Ltd. (stock code: 02575.HK), a non wholly-owned subsidiary of Sihuan Pharmaceutical Holdings Group Ltd., for the listing and permission to deal in 357,245,794 H Shares. These H Shares are converted from previously Unlisted Shares as part of the proposed H Share Full Circulation and Conversion and Listing initiative.
• Substantial Share Conversion: The conversion and listing of this significant number of shares represents a major step in enhancing the liquidity and accessibility of Xuanzhu Biopharm’s shares for public investors.
• Completion Requirements: The completion of the H Share Full Circulation and Conversion and Listing is subject to fulfilling all other relevant conditions.
• Shareholding Structure: Investors are advised to refer to the insider information announcement published by Xuanzhu Biopharm on 17 April 2026 for detailed information on the shareholding structure both before and after the Conversion and Listing. This could affect the distribution and control of shares within the company.

Background on Xuanzhu Biopharm

Xuanzhu Biopharm was listed on the Main Board of The Stock Exchange of Hong Kong Limited in October 2025 (stock code: 02575.HK). The company is an innovative pharmaceutical enterprise rooted in China, with a global perspective. Xuanzhu focuses on critical disease areas such as digestion, oncology, and non-alcoholic steatohepatitis. It is committed to the research, development, production, and commercialization of class 1 innovative drugs with proprietary intellectual property rights.

Xuanzhu boasts a first-class R&D team, with all core personnel highly experienced in new drug development. The company operates two key R&D platforms: small molecule chemistry and large molecule biopharmaceuticals. These dual engines drive innovation, resulting in a robust product pipeline that includes small molecule drugs, biopharmaceuticals, and antibody-drug conjugates (ADC). Xuanzhu’s strategy is to meet unmet major clinical needs and to become a leading innovative pharmaceutical company with independent R&D, production, and sales capabilities.

Background on Sihuan Pharmaceutical Holdings Group Ltd.

Founded in 2001 and listed in Hong Kong since 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical company driven by innovation. It operates an independent, advanced R&D platform, maintains a rich global product pipeline, and demonstrates strong capabilities in product registration. The company also has a full dosage form production platform characterized by high efficiency and low cost, supported by a mature and robust sales system.

Sihuan Pharmaceutical’s strategic goal is the full promotion of a “two-wheel drive strategy” encompassing both medical aesthetics and biopharmaceutical businesses. The Group aims to establish itself as a leading medical aesthetics and biopharmaceutical company in China.

Shareholder Information and Potential Price Sensitivity

• Liquidity Boost: The approval of H Share Full Circulation for Xuanzhu Biopharm is a significant development that will enhance the liquidity and tradability of shares, potentially attracting new investors and increasing trading volumes.
• Shareholding Changes: The conversion and listing process may result in changes to Xuanzhu’s shareholding structure, which could impact shareholder control and the future direction of the company. This information is crucial for both current and prospective investors.
• Strategic Growth: The move aligns with Sihuan Pharmaceutical’s broader strategy to strengthen its position in the medical aesthetics and biopharmaceutical sectors, potentially leading to further growth and value creation.
• Price Sensitivity: As this announcement relates to a substantial increase in the number of listed shares and improved liquidity, it is potentially price sensitive and could affect the share value of both Xuanzhu Biopharm and Sihuan Pharmaceutical Holdings Group Ltd.

Board and Management

As of the announcement date, the executive directors of Sihuan Pharmaceutical Holdings Group Ltd. are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling, and Ms. Miao Guili. Independent non-executive directors include Mr. Tsang Wah Kwong, Dr. Zhu Xun, and Mr. Wang Guan.

Conclusion

This voluntary announcement represents a significant milestone for both Sihuan Pharmaceutical and its subsidiary, Xuanzhu Biopharm. The approval for H Share Full Circulation and the listing of converted shares is a substantial step in improving market access, liquidity, and shareholder value. Investors are advised to monitor further developments and review the detailed shareholding structure changes as disclosed by Xuanzhu Biopharm.

Disclaimer

This article is intended for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions. The information provided herein is based on public announcements and may be subject to further updates or changes.

View SIHUAN PHARM Historical chart here